Sentynl Therapeutics acquires Eiger BioPharmaceuticals’ Zokinvy program to expand portfolio in rare diseases
Sentynl Therapeutics, Inc., a U.S.-based biopharmaceutical company wholly owned by Zydus Lifesciences, Ltd. (Zydus Group), has closed the acquisition of Eiger BioPharmaceuticals, Inc.’s Zokinvy (lonafarnib) program. Zokinvy is the only FDA-approved treatment for progeria, specifically Hutchinson-Gilford progeria syndrome (HGPS) and processing-deficient progeroid laminopathies (PDPL), affecting children from 12 months and older. Financial terms of the […]
